Also, the long-term safety of GLP-1 agonists is still unknown
Diabetes, insulin resistance, and obesity are responsible for the pathological manifestations of non-alcoholic steatohepatitis (NASH)
Clinically, half-life matters for three reasons: (1) missed dosesyou may still have some drug on board for days
Long-term outcomes: About half of patients lost at least 15% of their weight, and one-third lost 20% or more
Contact your GP, prescribing clinician, or call 999/111 if you experience: Severe or persistent vomiting or abdominal pain Signs of pancreatitis : severe upper abdominal pain, which may radiate to the back, with or without vomiting this requires urgent medical assessment Symptoms of a serious allergic reaction : rash, swelling of the face, lips, tongue or throat, or difficulty breathing These are rare but important safety signals, as outlined in the Wegovy Summary of Product Characteristics (SmPC) approved by the MHRA
Instead of searching through scattered resources and trying to piece together dosing information from multiple sources, members receive comprehensive protocols tailored to their specific vial size, concentration, and treatment goals
